Ecloud Co., Ltd.
“NUProtein”, which aims to solve food and medical problems with protein synthesis technology, will start raising funds for the second time through ecloud on January 7
– Accelerating the industrialization of cultured meat and regenerative medicine with a unique Japanese technology that reduces protein production costs –
Ecloud Co., Ltd. (Chuo-ku, Tokyo, CEO: Naohiko Hatae, hereinafter “Ecloud”), which provides a stock investment type crowdfunding service, will raise “NUProtein” for the second time following 2021. ) has started pre-disclosure. We will start accepting investment applications from 9:00 am on Saturday, January 7, 2023. (Details: https://ecrowd.co.jp/projects/17)
[Image 1
Ecloud, which provides “stock investment crowdfunding” that allows you to invest in unlisted venture companies through the Internet, will start accepting applications for “NUProtein” (17th project) from January 7, 2023. I will.
Overview of offering for the 17th project
Company name: NUProtein Co., Ltd.
Business overview: Manufacture and sale of cell-free protein synthesis reagent kits
Scheduled recruitment period: Start: Saturday, January 7, 2023 – End: Sunday, January 15, 2023
Target amount: 12.6 million yen (Maximum amount: 69.3 million yen) Use of funds: Patent expenses, R&D expenses, etc.
Taking on the challenge of a rice-derived protein business that enables the mass production of “growth factors” essential for cultured meat
NUProtein is a bio-venture that provides technologies for cheap, fast, and safe mass production of protein synthesis, mainly for the fields of cultured meat and regenerative medicine.
Synthesis technology for artificial proteins such as cultured meat requires stem cells, which are special cells that create cells, and special proteins called “growth factors” that promote cell
proliferation and differentiation. However, growth factors have traditionally been extremely expensive, accounting for more than 90% of manufacturing costs, and have been a bottleneck in protein synthesis technology.
NUProtein has a proprietary technology that efficiently and
inexpensively produces growth factors. In October 2021, NUProtein raised 57,380,000 yen from 343 individual investors on ecloud, and worked on business development for overseas and improvement of its core technology, protein synthesis technology. In addition, we have started business negotiations with multiple overseas cultured meat and cultured fish meat manufacturers for full-scale transactions, and are conducting joint development with multiple major manufacturers. [Image 2
Up until now, NUProtein has provided growth factors made from wheat germ, but as we proceed with business negotiations with manufacturers, we will establish technology using genetically modified rice, which is easier to mass-produce. By doing so, we would like to support the industrialization of protein synthesis on both wheels.
With the aim of establishing a new technological base using rice and expanding sympathy for the business, we plan to raise funds from individual investors again through the stock investment type crowdfunding “ecloud”.
3 Points to Note About “NUProtein”
Aiming to be a platform that supports the industrialization of cultured meat, which is expected to grow to 70 trillion yen in 2040 Entrepreneur who has engaged in over 100 IP developments and CVCs at Panasonic deploys technology from Nagoya University to the world Started joint research with multiple listed companies, and is in business negotiations with multiple overseas cultured fish meat manufacturers for full-scale introduction
For more information, please visit the eCloud recruitment page.
[Table 2: https://prtimes.jp/data/corp/54017/table/39_1_5897ff050e9845501112deeafb9bdce2.jpg ]
“NUProtein” Minami answers questions from investors
Until January 2, 2023 (Monday / holiday), we will accept questions for Mr. Minami of “NUProtein”. Answers to questions from investors will be posted on the recruitment page (https://ecrowd.co.jp/projects/17) around January 4 (Wednesday).
If you have any questions about our business, strategy, fundraising, etc., please take this opportunity to ask us.
*Please note that we may not be able to answer depending on the content of your question.
What is “stock investment type crowdfunding” that allows you to become a shareholder of NUProtein from about 100,000 yen?
Ecloud provides a mechanism for unlisted startups to raise funds from individual investors via the Internet, “Equity Investment
Crowdfunding”.
[Image 3
Startups are once again attracting attention as a driving force behind Japan’s economic growth and problem solving, such as the government’s “startup development five-year plan”. On the other hand, fundraising is a bottleneck for startups that have just been founded. “Equity investment type crowdfunding” is a mechanism that allows unlisted start-up companies with remarkable growth to raise funds of less than 100 million yen per year. It’s a new way of fundraising.
In addition, until now, opportunities for individual investors to invest in unlisted venture companies have been extremely limited, and only a small number of managers and wealthy people called angel investors have been able to invest. By utilizing “stock investment type crowdfunding”, the hurdles for individual investors to invest in venture companies have been reduced.
*This press release is a document to publicly announce the decision of Ecloud’s 17th project, and is not prepared for the purpose of soliciting investment.
◆ Overview of eCloud Co., Ltd.
Trade name: Ecloud Co., Ltd.
Financial Instruments Business Operator Kanto Local Finance Bureau Director (Kinsho) No. 3181
Member Association: Japan Securities Dealers Association
Head office location: 1-5-20 Yaesu, Chuo-ku, Tokyo 103-0028 Tokyo Tatemono Yaesu Sakura-dori Building 3F
Representative Director: Naohiko Hatae
Service site: https://ecrowd.co.jp/
Corporate site: https://corp.ecrowd.co.jp/
◆Overview of NUProtein Co., Ltd.
Head office location: 3-20-1 Showacho, Tokushima City, 770-0942 Representative Director: Kennao Minami
Service site: http://nuprotein.jp/ja/
Details about this release:
https://prtimes.jp/main/html/rd/p/000000039.000054017.html
MAIL:cr@prtimes.co.jp